WallStSmart
HURA

TuHURA Biosciences Inc

NASDAQ: HURA · HEALTHCARE · BIOTECHNOLOGY

$2.05
+0.99% today

Updated 2026-09-11

Market cap
$133.19M
P/E ratio
P/S ratio
EPS (TTM)
$-0.54
Dividend yield
52W range
$0 – $3
Volume
0.3M

TuHURA Biosciences Inc (HURA) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20122014201520162017201820192020202120222023202420252026
Operating cash flow$-11385.00$-5.52M$-3.85M$-5.15M$-8.02M$-9.85M$-6.33M$-7.93M$-18.86M$-6.56M$-7.51M$-11.95M$-14.73M$-27.63M
Capital expenditures$5.00$0.00$3.85M$4.00$1.00$9.85M$5.00$0.00$8000.00$3280.00$36277.00$79224.00$57906.00$76083.00
Depreciation
Stock-based comp$654529.00$218275.00$478890.00$1.96M$6.42M
Free cash flow$-11390.00$-5.52M$-7.71M$-5.15M$-8.02M$-19.70M$-6.33M$-7.93M$-18.87M$-6.57M$-7.54M$-12.03M$-14.79M$-27.71M
Investing cash flow
Financing cash flow
Dividends paid$6267.00$8356.00$8356.00$8356.00$8356.00$8000.00$8000.00$8000.00$8000.00$6000.00$0.00$8356.00
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does HURA generate?

HURA produced $-27.71M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is HURA's balance sheet healthy?

HURA holds $3.62M in cash and equivalents against — in long-term debt, on $20.93M of shareholder equity. That debt is best read against the cash flow the business throws off each year.